Clinical Trial Update: A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum [Phase 1]

View source ↗

Summary

Phase I study evaluating AZD6244 with capecitabine and radiotherapy in non-metastatic rectal adenocarcinoma; the trial was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-metastatic Rectal Cancer
• Rectal Adenocarcinoma

Drugs mentioned

• AZD6244 (selumetinib)
• Capecitabine (capecitabine)
• Radiotherapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non-Metastatic Adenocarcinoma of the Rectum | Phase 1 | Status: TERMINATED | Results posted: 2021-12-01